Preventing acute gout when starting allopurinol therapy. Colchicine or NSAIDs?

Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol (2011) 1.23

Diagnosis and management of gout: a rational approach. Postgrad Med J (2005) 0.89

Preventing acute gout when starting allopurinol therapy. Colchicine or NSAIDS? Med J Aust (1994) 0.75

Successful use of allopurinol in a patient on dialysis. BMJ Case Rep (2012) 0.75

Preventing acute gout when starting allopurinol therapy. Colchicine or NSAIDS? Med J Aust (1994) 0.75

Nonsteroidal antiinflammatory drugs--differences and similarities. N Engl J Med (1991) 3.05

Pattern of non-steroidal anti-inflammatory drug use in Australia 1990-1994. A report from the Drug Utilization Sub-Committee of the Pharmaceutical Benefits Advisory Committee. Med J Aust (1996) 2.78

COX-2 inhibitors. Med J Aust (2000) 2.76

Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med (1994) 2.74

A comparison of outcomes in osteoarthritis patients undergoing total hip and knee replacement surgery. Osteoarthritis Cartilage (2001) 2.54

A crystalline fragment of the double helix: the structure of the dinucleoside phosphate guanylyl-3',5'-cytidine. Proc Natl Acad Sci U S A (1973) 2.39

Outcomes after hip or knee replacement surgery for osteoarthritis. A prospective cohort study comparing patients' quality of life before and after surgery with age-related population norms. Med J Aust (1999) 2.28

Giving and receiving of gifts between pharmaceutical companies and medical specialists in Australia. Intern Med J (2006) 2.19

Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med (1987) 2.17

Risk taking in patients with rheumatoid arthritis: are the risks of haemopoietic stem cell transplantation acceptable? Rheumatology (Oxford) (1999) 2.09

RNA double-helical fragments at atomic resolution. II. The crystal structure of sodium guanylyl-3',5'-cytidine nonahydrate. J Mol Biol (1976) 2.07

The patient is the teacher: ambulatory patient-centred student-based interprofessional education where the patient is the teacher who improves patient care outcomes. Intern Med J (2013) 2.03

Evaluation of the accuracy and reproducibility of ambulatory blood pressure monitoring in the very elderly using the Takeda TM-2420. J Hum Hypertens (1994) 1.92

Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet (2000) 1.76

A survey of current prescribing practices of antiinflammatory and urate lowering drugs in gouty arthritis in the province of Ontario. J Rheumatol (1988) 1.71

Copper-salicylate gel for pain relief in osteoarthritis: a randomised controlled trial. Med J Aust (1997) 1.66

The clinical and immunological effects of pulse methylprednisolone therapy in rheumatoid arthritis. I. Clinical effects. J Rheumatol (1988) 1.60

Nonsteroidal antiinflammatory drugs in rheumatoid arthritis and osteoarthritis: support for the concept of "responders" and "nonresponders". Arthritis Rheum (1997) 1.59

Serum immunoreactive gastrin: specificity for rheumatoid arthritis, bimodality of distribution, and failure of effect of anti-inflammatory drugs. Ann Rheum Dis (1976) 1.42

Overdose with chloral hydrate: a pharmacological and therapeutic review. Med J Aust (1989) 1.42

The cycling of combination antirheumatic drug therapy in rheumatoid arthritis. Br J Rheumatol (1990) 1.41

Wrong questions, wrong answers? Are we getting the drugs we need? Clin Pharmacol Ther (2012) 1.41

Clinical pharmacokinetics of the salicylates. Clin Pharmacokinet (1985) 1.39

Is diet important in rheumatoid arthritis? Br J Rheumatol (1991) 1.39

Methotrexate in rheumatoid arthritis. Aust N Z J Med (1988) 1.38

Does the availability of therapeutic drug monitoring, computerised dose recommendation and prescribing decision support services promote compliance with national gentamicin prescribing guidelines? Intern Med J (2015) 1.38

Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol (1989) 1.36

The bone and joint decade: 2000-2010. Med J Aust (2000) 1.34

Antirheumatic medication during lactation. Br J Rheumatol (1985) 1.33

Septic arthritis in patients with rheumatoid disease: a still underdiagnosed complication. J Rheumatol (1976) 1.31

Abnormal bowel permeability in ankylosing spondylitis and rheumatoid arthritis. J Rheumatol (1985) 1.29

Effects of budesonide and fluticasone on 24-hour plasma cortisol. A dose-response study. Am J Respir Crit Care Med (1997) 1.28

Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. Br J Pharmacol (2008) 1.27

Patient self-efficacy and health locus of control: relationships with health status and arthritis-related expenditure. Rheumatology (Oxford) (2005) 1.25

Plasma aspirin esterases in normal individuals, patients with alcoholic liver disease and rheumatoid arthritis: characterization and the importance of the enzymic components. Eur J Clin Invest (1980) 1.25

Living with rheumatoid arthritis: expenditures, health status, and social impact on patients. Ann Rheum Dis (2002) 1.23

A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. Br J Clin Pharmacol (1988) 1.22

Nucleic acid-mutagen interactions: crystal structure of adenylyl-3',5'-uridine plus 9-aminoacridine. Nature (1975) 1.20

How safe are anti-rheumatic drugs? A study of possible iatrogenic deaths in patients with rheumatoid arthritis. Health Bull (Edinb) (1975) 1.19

Protein binding of some non-steroidal anti-inflammatory drugs in rheumatoid arthritis. Clin Pharmacokinet (1982) 1.19

Effects of granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-2, interferon-gamma (IFN-gamma), tumour necrosis factor-alpha (TNF-alpha) and IL-6 on the production of immunoreactive IL-1 and TNF-alpha by human monocytes. Clin Exp Immunol (1991) 1.17

RNA double helices generated from crystal structures of double helical dinucleoside phosphates. Biochem Biophys Res Commun (1976) 1.16

Patterns of plasma concentrations and urinary excretion of salicylate in rheumatoid arthritis. Clin Pharmacol Ther (1977) 1.15

Assessment of nonsteroidal anti-inflammatory drug combinations by the polyurethane sponge implantation model in the rat. Ann Rheum Dis (1983) 1.13

Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme? Intern Med J (2007) 1.11

Haemopoietic stem cell transplantation for autoimmune diseases. Br J Haematol (1997) 1.11

Effect of gonadal steroids on the production of IL-1 and IL-6 by blood mononuclear cells in vitro. Clin Exp Rheumatol (1993) 1.11

Lymphocyte subsets and inflammatory indices in synovial fluid and blood of patients with rheumatoid arthritis. J Rheumatol (1984) 1.10

Binding of haptoglobin, inter-alpha-trypsin inhibitor, and alpha 1 proteinase inhibitor to synovial fluid hyaluronate and the influence of these proteins on its degradation by oxygen derived free radicals. Ann Rheum Dis (1988) 1.08

Inhibition of neutrophil chemotaxis in methotrexate-treated rheumatoid arthritis patients. Rheumatol Int (1988) 1.08

Chinese herbal arthritis cure and agranulocytosis. Med J Aust (1978) 1.07

NSAID and osteoarthritis--help or hindrance? J Rheumatol (1982) 1.07

Anabolic-androgenic steroids: medical assessment of present, past and potential users. Med J Aust (2000) 1.05

Two knees or not two knees? Patient costs and outcomes following bilateral and unilateral total knee joint replacement surgery for OA. Osteoarthritis Cartilage (2004) 1.04

Indomethacin--aspirin interaction: a clinical appraisal. Br Med J (1975) 1.04

Determinants of willingness to pay for hip and knee joint replacement surgery for osteoarthritis. Rheumatology (Oxford) (2000) 1.04

Articular chondrocalcinosis in a hospital population: an Australian experience. Aust N Z J Med (1984) 1.04

Anti-rheumatic drug interactions. Clin Rheum Dis (1984) 1.04

Interleukin-1 secretion by peripheral blood monocytes and synovial macrophages from patients with rheumatoid arthritis. J Rheumatol (1987) 1.04

Concentration-effect relationship of hydroxychloroquine in rheumatoid arthritis--a cross sectional study. J Rheumatol (1993) 1.04

Determinants of disability in rheumatoid arthritis. Br J Rheumatol (1988) 1.03

Chiral inversion of 2-arylpropionic acid non-steroidal anti-inflammatory drugs--1. In vitro studies of ibuprofen and flurbiprofen. Biochem Pharmacol (1989) 1.03

The problems and pitfalls of NSAID therapy in the elderly (Part I). Drugs Aging (1991) 1.02

Alterations in prednisolone disposition as a result of time of administration, gender and dose. Br J Clin Pharmacol (1984) 1.01

Methylprednisolone infusion therapy in rheumatoid arthritis patients. The effect on synovial fluid lymphocyte subsets and inflammatory indices. Arthritis Rheum (1986) 1.00

Relationship of serum naproxen concentration to efficacy in rheumatoid arthritis. Clin Pharmacol Ther (1982) 1.00

Cytokine regulation of human monocyte interleukin-1 (IL-1) production in vitro. Enhancement of IL-1 production by interferon (IFN) gamma, tumour necrosis factor-alpha, IL-2 and IL-1, and inhibition by IFN-alpha. Clin Exp Immunol (1990) 0.99

Stereoselective disposition of ibuprofen and flurbiprofen in rats. Chirality (1990) 0.99

Variations in response to non-steroidal anti-inflammatory drugs. Br J Clin Pharmacol (1987) 0.99

Comparison of methylprednisolone (1 g i.v.) with prednisolone (1 g orally) in rheumatoid arthritis: a pharmacokinetic and clinical study. J Rheumatol (1988) 0.98

Structural requirements for drug binding to site II on human serum albumin. Mol Pharmacol (1983) 0.98

The clinical and immunological effects of pulse methylprednisolone therapy in rheumatoid arthritis. II. Effects on immune and inflammatory indices in peripheral blood. J Rheumatol (1988) 0.98

The subcutaneous air pouch model of synovium and the inflammatory response to heat aggregated gammaglobulin. Agents Actions (1986) 0.98

Circulating cytokine levels in patients with rheumatoid arthritis: results of a double blind trial with sulphasalazine. Ann Rheum Dis (1992) 0.97

Interactions of anti-rheumatic drugs. Agents Actions Suppl (1977) 0.97

Clinical rheumatology training of Australian medical students. A national survey of 1991 graduates. Med J Aust (1993) 0.97

Alterations in prednisolone disposition as a result of oral contraceptive use and dose. Br J Clin Pharmacol (1984) 0.97

Metformin therapy in patients with chronic kidney disease. Diabetes Obes Metab (2012) 0.96

Corticosteroid injection for osteoarthritis of the knee: peripatellar compared to intra-articular route. Clin Exp Rheumatol (1990) 0.96

Flurbiprofen-aspirin interaction: a double-blind crossover study. Curr Med Res Opin (1977) 0.96

Articular manifestations of acromegaly. Aust N Z J Med (1988) 0.96

A survey of outcome measurement procedures in routine rheumatology outpatient practice in Australia. J Rheumatol (1999) 0.95

Non-steroidal anti-inflammatory drug induced upper gastrointestinal haemorrhage and bleeding. Med J Aust (1993) 0.95

The effect of gold sodium thiomalate and auranofin on lipopolysaccharide-induced interleukin-1 production by blood monocytes in vitro: variation in healthy subjects and patients with arthritis. Clin Exp Immunol (1990) 0.94

Comparative effectiveness of 5 analgesics in patients with rheumatoid arthritis and osteoarthritis. J Rheumatol (1983) 0.94

Type IIA secretory phospholipase A2 up-regulates cyclooxygenase-2 and amplifies cytokine-mediated prostaglandin production in human rheumatoid synoviocytes. J Immunol (2000) 0.93

Long-term outcome of autoimmune disease following allogeneic bone marrow transplantation. Arthritis Rheum (1998) 0.93

A comparison of plasma methylprednisolone concentrations following intra-articular injection in patients with rheumatoid arthritis and osteoarthritis. Aust N Z J Med (1983) 0.93

Current practice in antimalarial drug prescribing in rheumatoid arthritis. J Rheumatol (1986) 0.93

Protein binding of non-steroidal anti-inflammatory drugs in plasma and synovial fluid of arthritic patients. Br J Clin Pharmacol (1983) 0.93

6-Mercaptopurine-related leucopenia and in vivo xanthine oxidase activity. Lancet (1986) 0.92

Interactions between non-steroidal anti-inflammatory drugs and antihypertensives and diuretics. Aust N Z J Med (1986) 0.92

Inhibition of AP-1 binding and transcription by gold and selenium involving conserved cysteine residues in Jun and Fos. Proc Natl Acad Sci U S A (1995) 0.91

Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects. Br J Clin Pharmacol (1996) 0.91

An analysis of the relationship between psychological morbidity and disease activity in rheumatoid arthritis. J Rheumatol (1988) 0.91

Increased expression of human type IIa secretory phospholipase A2 antigen in arthritic synovium. Ann Rheum Dis (1998) 0.91

Migration of blood and synovial fluid neutrophils obtained from patients with rheumatoid arthritis. Clin Exp Immunol (1980) 0.90

A phase I/II dose escalation study of intensified cyclophosphamide and autologous blood stem cell rescue in severe, active rheumatoid arthritis. Arthritis Rheum (1999) 0.90